How many doses of Reclast (zoledronic acid) can be administered in a 12‑month period?

Reclast Dosing Frequency

For osteoporosis treatment, Reclast (zoledronic acid) 5 mg is administered once yearly, and for osteoporosis prevention, once every two years—meaning you can receive 1 dose per year for treatment or 1 dose every 2 years for prevention. 1

Approved Dosing Schedules by Indication

The number of allowed doses depends entirely on your clinical indication:

Postmenopausal Osteoporosis Treatment

• 5 mg IV once yearly 2, 1
• This can continue indefinitely, though duration of therapy is typically reassessed after 3-5 years based on fracture risk 3

Osteoporosis Prevention (Osteopenia)

• 5 mg IV once every 2 years 2, 1
• This means 1 dose every 24 months

Glucocorticoid-Induced Osteoporosis

• 5 mg IV once yearly 1

Paget's Disease

• 5 mg IV as a single dose 4
• Retreatment is seldom required within 5 years 4

Men with Osteoporosis

• 5 mg IV once yearly for up to 2 doses 1

Important Dosing Considerations

For metastatic bone disease (breast cancer, multiple myeloma), the dosing is completely different: 4 mg IV monthly for patients with suboptimal response, continuing for at least 4 years 5. In patients achieving complete or very good partial response, 12-48 months may be adequate 5.

Duration of Therapy

The evidence supports:

• Original trials continued treatment for up to 24 months in metastatic disease 6
• For osteoporosis, there is a trend toward interrupting therapy after 5-10 years to reassess need 2
• Recent evidence shows a single 5 mg dose maintains bone density for 9-10 years in some patients 7
• Two doses given 5 years apart prevented vertebral fractures over 10 years in early postmenopausal women 8

Critical Safety Parameters

You cannot receive Reclast if:

• Creatinine clearance < 35 mL/min/1.73 m² 2, 9, 1
• You have hypocalcemia (must be corrected first) 1

Before each dose:

• Serum creatinine must be monitored 6
• Calcium and vitamin D status must be optimized 6, 5, 10
• Vitamin D deficiency should be corrected to prevent hypocalcemia 10

Common Pitfall

Do not confuse osteoporosis dosing (5 mg yearly) with cancer-related bone disease dosing (4 mg monthly)—these are completely different indications with different dose frequencies 1, 11. The higher frequency monthly dosing carries increased risks of osteonecrosis of the jaw (1.5-2.1% with monthly dosing vs. 0.8-2% with 6-monthly dosing) 12.